156 related articles for article (PubMed ID: 31374426)
1. The Impact of Price Negotiations on Public Procurement Prices and Access to 8 Innovative Cancer Medicines in a Middle-Income Country: The Case of Mexico.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Value Health Reg Issues; 2019 Dec; 20():129-135. PubMed ID: 31374426
[TBL] [Abstract][Full Text] [Related]
2. Reforming antiretroviral price negotiations and public procurement: the Mexican experience.
Adesina A; Wirtz VJ; Dratler S
Health Policy Plan; 2013 Jan; 28(1):1-10. PubMed ID: 22375026
[TBL] [Abstract][Full Text] [Related]
3. A new entity for the negotiation of public procurement prices for patented medicines in Mexico.
Gómez-Dantés O; Wirtz VJ; Reich MR; Terrazas P; Ortiz M
Bull World Health Organ; 2012 Oct; 90(10):788-92. PubMed ID: 23109747
[TBL] [Abstract][Full Text] [Related]
4. Prices & availability of common medicines at six sites in India using a standard methodology.
Kotwani A; Ewen M; Dey D; Iyer S; Lakshmi PK; Patel A; Raman K; Singhal GL; Thawani V; Tripathi S; Laing R
Indian J Med Res; 2007 May; 125(5):645-54. PubMed ID: 17642500
[TBL] [Abstract][Full Text] [Related]
5. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
[TBL] [Abstract][Full Text] [Related]
6. Where are we now: assessing the price, availability and affordability of essential medicines in Delhi as India plans free medicine for all.
Kotwani A
BMC Health Serv Res; 2013 Jul; 13():285. PubMed ID: 23885985
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunities.
Chaumont C; Bautista-Arredondo S; Calva JJ; Bahena-González RI; Sánchez-Juárez GH; González de Araujo-Muriel A; Magis-Rodríguez C; Hernández-Ávila M
Salud Publica Mex; 2015; 57 Suppl 2():s171-82. PubMed ID: 26545133
[TBL] [Abstract][Full Text] [Related]
8. Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.
Moye-Holz D; van Dijk JP; Reijneveld SA; Hogerzeil HV
Global Health; 2017 Aug; 13(1):53. PubMed ID: 28764738
[TBL] [Abstract][Full Text] [Related]
9. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Cameron A; Ewen M; Ross-Degnan D; Ball D; Laing R
Lancet; 2009 Jan; 373(9659):240-9. PubMed ID: 19042012
[TBL] [Abstract][Full Text] [Related]
10. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.
Yang H; Dib HH; Zhu M; Qi G; Zhang X
Health Policy Plan; 2010 May; 25(3):219-29. PubMed ID: 19955093
[TBL] [Abstract][Full Text] [Related]
11. The prices people pay for medicines in Zimbabwe.
Gavaza P; Simoyi T; Makunike B; Maponga CC
Cent Afr J Med; 2009; 55(1-4):14-9. PubMed ID: 21977842
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
[TBL] [Abstract][Full Text] [Related]
13. Pricing and availability of some essential child specific medicines in Odisha.
Swain TR; Rath B; Dehury S; Tarai A; Das P; Samal R; Samal S; Nayak H
Indian J Pharmacol; 2015; 47(5):496-501. PubMed ID: 26600637
[TBL] [Abstract][Full Text] [Related]
14. Negotiating antiretroviral drug prices: the experience of the Andean countries.
Seoane-Vazquez E; Rodriguez-Monguio R
Health Policy Plan; 2007 Mar; 22(2):63-72. PubMed ID: 17299024
[TBL] [Abstract][Full Text] [Related]
15. Availability and affordability of essential medicines for children in the Western part of Ethiopia: implication for access.
Sado E; Sufa A
BMC Pediatr; 2016 Mar; 16():40. PubMed ID: 26979737
[TBL] [Abstract][Full Text] [Related]
16. Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.
Wirtz VJ; Santa-Ana-Tellez Y; Trout CH; Kaplan WA
Health Policy Plan; 2012 Dec; 27(8):638-48. PubMed ID: 22367770
[TBL] [Abstract][Full Text] [Related]
17. Access to innovative cancer medicines in a middle-income country - the case of Mexico.
Moye-Holz D; Soria Saucedo R; van Dijk JP; Reijneveld SA; Hogerzeil HV
J Pharm Policy Pract; 2018; 11():25. PubMed ID: 30386627
[TBL] [Abstract][Full Text] [Related]
18. Delivery of Essential Medicines to Primary Care Institutions and its Association with Procurement Volume and Price: A Case Study in Hubei Province, China.
Tang Y; Liu C; Zhang X
Appl Health Econ Health Policy; 2017 Feb; 15(1):57-64. PubMed ID: 27613726
[TBL] [Abstract][Full Text] [Related]
19. Prices and availability of locally produced and imported medicines in Ethiopia and Tanzania.
Ewen M; Kaplan W; Gedif T; Justin-Temu M; Vialle-Valentin C; Mirza Z; Regeer B; Zweekhorst M; Laing R
J Pharm Policy Pract; 2017; 10():7. PubMed ID: 28116107
[TBL] [Abstract][Full Text] [Related]
20. Enhancing medicine price transparency through price information mechanisms.
Hinsch M; Kaddar M; Schmitt S
Global Health; 2014 May; 10():34. PubMed ID: 24885767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
